亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

医学 内科学 突变 癌症 克拉斯 肺癌 癌症研究 遗传学 生物 基因
作者
Pasi Antero Janne,Gregory J. Riely,Shirish M. Gadgeel,Rebecca Suk Heist,Sai‐Hong Ignatius Ou,Jose M. Pacheco,Melissa Lynne Johnson,Joshua K. Sabari,Konstantinos Leventakos,Edwin H. Yau,Lyudmila A. Bazhenova,Marcelo Vailati Negrao,Nathan A. Pennell,Jun Zhang,Kenna Lynn Anderes,Hirak Der‐Torossian,Thian San Kheoh,Karen Velastegui,Xiaohong Yan,James G. Christensen
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:387 (2): 120-131 被引量:1061
标识
DOI:10.1056/nejmoa2204619
摘要

BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
baishier发布了新的文献求助10
1秒前
2秒前
wise111发布了新的文献求助10
3秒前
6秒前
D4C发布了新的文献求助10
11秒前
薄荷水完成签到,获得积分10
11秒前
王平安完成签到 ,获得积分10
12秒前
13秒前
行走的鱼发布了新的文献求助10
13秒前
hsyyk发布了新的文献求助10
13秒前
隐形曼青的应助被baishier采纳,获得10
16秒前
Leofar完成签到 ,获得积分10
16秒前
17秒前
小蘑菇的应助被美琦采纳,获得10
19秒前
赘婿的应助被Ppop采纳,获得30
20秒前
20秒前
巨型肥猫发布了新的文献求助10
20秒前
四川南丁格尔完成签到 ,获得积分10
21秒前
zx的应助被涵泽采纳,获得10
22秒前
脑洞疼的应助被wise111采纳,获得10
23秒前
24秒前
25秒前
25秒前
小苏完成签到 ,获得积分10
26秒前
hsyyk完成签到,获得积分10
26秒前
27秒前
NASA_FAST完成签到 ,获得积分10
27秒前
称心的寻桃完成签到 ,获得积分10
30秒前
33秒前
Ppop发布了新的文献求助30
33秒前
Laluna的应助被suicone采纳,获得10
33秒前
李健的小迷弟的应助被hdse采纳,获得10
34秒前
34秒前
35秒前
37秒前
38秒前
巨型肥猫完成签到,获得积分10
38秒前
LYZSh发布了新的文献求助10
39秒前
大个的应助被行走的鱼采纳,获得10
39秒前
vivi完成签到 ,获得积分10
42秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778